Cargando…
Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
BACKGROUND: This study was to evaluate the Turkish regulatory review process and timelines between 2016 and 2018 with a view to assess the changes that had taken place since the previous study, which evaluated the Turkish review processes and timelines 2013 to 2015. METHODS: Data related to the Turk...
Autores principales: | Koyuncu, Oguzhan, Gursoz, Hakki, Alkan, Ali, Cetintas, Hacer Coskun, Pasaoglu, Tuncay, Mashaki Ceyhan, Emel, Walker, Stuart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008400/ https://www.ncbi.nlm.nih.gov/pubmed/32116658 http://dx.doi.org/10.3389/fphar.2019.01557 |
Ejemplares similares
-
The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore
por: Mashaki Ceyhan, Emel, et al.
Publicado: (2018) -
Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients’ Access to Medicines
por: Keyter, Andrea, et al.
Publicado: (2019) -
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
por: Rahalkar, Hasumati, et al.
Publicado: (2018) -
Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2022) -
Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2023)